In a report released today, Scott Henry from Roth Capital upgraded Lemaitre Vascular (NASDAQ: LMAT) to Buy, with a price target of $34. The company’s shares closed on Friday at $28.53, close to its 52-week low of $26.99.
According to TipRanks.com, Henry is a 4-star analyst with an average return of 4.4% and a 43.4% success rate. Henry covers the Healthcare sector, focusing on stocks such as Natus Medical Inc, Intec Pharma Ltd, and Catalyst Pharma.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Lemaitre Vascular with a $33.33 average price target, implying a 16.8% upside from current levels. In a report released today, Barrington also upgraded the stock to Buy with a $34 price target.
The company has a one-year high of $41.28 and a one-year low of $26.99. Currently, Lemaitre Vascular has an average volume of 133.5K.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of LMAT in relation to earlier this year. Most recently, in August 2018, Joseph Pellegrino, the CFO of LMAT sold 501 shares for a total of $18,552.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
LeMaitre Vascular, Inc. is a medical device company, which engages in the provision of medical devices for the treatment of peripheral vascular disease. Its products include balloon catheters, carotid shunts, biologic patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, vascular grafts, and powered phlebectomy. The company was founded by George D. LeMaitre on November 28, 1983 and is headquartered in Burlington, MA.